Luo v. Spectrum Pharmaceuticals, Inc.

District Court, D. Nevada·Decided July 28, 2022·No. 2:21-cv-01612·Unknown

Opinion

DISTRICT OF NEVADA

Jose Chung Luo, individually and on behalf of all others similarly situated, Case No. 2:21-cv-01612-CDS-BNW Plaintiffs, v.

Spectrum Pharmaceuticals, Inc., et al, Order

Defendants. This is a securities class action case filed brought by Plaintiff Jose Chung Luo on behalf of himself and others who acquired Spectrum securities between December 27, 2018, and August 5, 2021. Before the Court are competing motions of appointment to be the lead plaintiff in this securities class action litigation. For the reasons set forth below, International Trading Group, Inc.’s motion for appointment of counsel and for appointment as lead plaintiff (ECF No. 18) are hereby GRANTED. The other motions for appointment (ECF Nos. 15, 16, 17, 20) are DENIED. I. Relevant Background Information On August 31, 2021, Plaintiff Luo filed the complaint identifying the nature of the case as “a federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018[,] and August 5, 2021.” ECF No. 1 at 2, ¶1. Luo sues under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Id. He alleges that Defendants made materially false and misleading statements about Rolontis, a developmental drug that Defendant Spectrum Pharmaceuticals planned to submit to the Food and Drug Administration for approval. Id. at 2-3, ¶4. On August 6, 2021, Spectrum announced receipt of a letter from the FDA regarding Rolontis, which cited deficiencies related to Spectrum’s manufacturing and indicated that re-inspection of Spectrum’s manufacturing facility would be necessary. Id. at 3, ¶5. Luo alleges that this news caused “Spectrum’s stock price [to fall] $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.” Id. at 3, ¶6. Due to the decline in Spectrum’s stock price, Luo argues that he and other class members have suffered significant losses and damages. Id. at 3, ¶7. On the same day that Luo filed suit, notice was issued pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”) advising potential class members of the claims alleged by Luo and of the 60-day deadline for class members to move to be appointed as lead plaintiff. ECF No. 17-2 at 2-4. On November 1, 2021, the final day of the deadline, five movants filed similar motions for appointment as lead plaintiff and requested this Court’s approval for their selection of counsel. ECF Nos. 15 (Mark Mehalic), 16 (Changyoung Jung), 17 (Mark Kozubal), 18 (International Trading Group, Inc. (“ITG”), 20 (Steven Dunkleberger). Jung, Mehalic, and Dunkleberger subsequently filed non-opposition responses to the other prospective lead plaintiffs’ motions. ECF Nos. 21, 22, 25. The remaining movants, Kozubal and ITG, both assert that they should be appointed lead plaintiff and filed responses and replies to the other’s motions. ECF Nos. 23, 24, 26, 27.1 Essentially, the parties dispute what method should be used to calculate whether Kozubal or ITG suffered greater losses. Compare ITG’s Response, ECF No. 23 at 2-3 with Kozubal’s Response, ECF No. 24 at 6-8. Both parties also attack each other’s adequacy to be lead plaintiff in this action. Compare ECF No. 23 at 3 with ECF No. 24 at 8-9.

1 Kozubal and ITG both filed their initial motions on November 1, 2021. Both responses were filed on November 15, 2021, and both replies were filed on November 22, 2021. ITG claims that it suffered the greatest loss, claiming an amount of $684,504.22. ECF No. 23 at 2. ITG further argues that Kozubal filed a “boilerplate” certification “lack[ing] any substantial information concerning Kozubal” and that the “dearth of information precludes a finding of adequacy.” Id. at 3. Kozubal claims that he lost $314,291.75. ECF No. 17 at 6. Kozubal contends that most of ITG’s losses are uncountable “in-and-out” losses, which when excluded, leave ITG with “compensable losses [of] no more than $54,921.” ECF No. 24 at 8. Kozubal further alleges that “there are practical reasons to refrain from appointing individuals who have primarily ‘in-and- out’ trades as lead plaintiffs” and that such in-and-out trading makes ITG “inadequate and atypical.” Id. ITG replied, asserting that Kozubal has failed to meet his burden to persuade this Court as to why ITG’s “in-and-out” losses are uncountable and that Kozubal inappropriately raised an argument in its response brief. See generally ECF No. 26. Kozubal also replied, asserting that ITG itself inappropriately raised an argument in its response brief. ECF No. 27 at 9-10. II. Legal Standard “A straightforward reading of the statutory language” of 15 U.S.C. § 78u-4(a) “discloses a clear path that the district court must follow in selecting the lead plaintiff.” In re Cavanaugh, 306 F.3d 726, 729 (9th Cir. 2002). The Act instructs district courts to select as lead plaintiff the one “most capable of adequately representing the interests of class members.” 15 U.S.C. § 78u- 4(a)(3)(B)(i). “The most capable plaintiff – and hence the lead plaintiff – is the one who has the greatest financial stake in the outcome of the case, so long as he meets the requirements of Rule 23.” Cavanaugh, 306 F.3d at 729. “In other words, the district court must compare the financial stakes of the various plaintiffs and determine which one has the most to gain from the lawsuit. It must then focus its attention on that plaintiff and determine, based on the information he has provided in his pleadings and declarations, whether he satisfies the requirements of Rule 23(a), in particular those of ‘typicality’ and ‘adequacy.’” Id. at 730 (emphasis in original). If the plaintiff with the largest financial stake in the controversy provides information that satisfies those requirements, then that plaintiff is presumptively most adequate. Id. Other plaintiffs may rebut the presumptive lead plaintiff’s showing that they satisfy Rule 23’s requirements. Id. “If the plaintiff with the greatest financial stake does not satisfy the Rule 23(a) criteria, the court must repeat the inquiry, this time considering the plaintiff with the next-largest financial stake, until it finds a plaintiff who is both willing to serve and satisfies the requirements of Rule 23.” Id. Finally, a straightforward application of the PSLRA mandates that this Court focus solely on the plaintiffs’ financial stake in the case; “so long as the plaintiff with the largest losses satisfies the typicality and adequacy requirements, he is entitled to lead plaintiff status, even if the district court is convinced that some other plaintiff would do a better job.” Id. at 732. III. Analysis The plaintiff with the greatest financial stake in this litigation is ITG. ITG also satisfies the adequacy and typicality requirements of Rule 23. Thus, ITG should be the lead plaintiff in this action.2 i. ITG Has Demonstrated the Greatest Financial Stake in this Case ITG has the greatest financial stake in this litigation because it claims greater losses than the other prospective lead plaintiffs. While the Ninth Circuit has no specific formula to

Free access — add to your briefcase to read the full text and ask questions with AI

Luo v. Spectrum Pharmaceuticals, Inc., (D. Nev. 2022).

Luo v. Spectrum Pharmaceuticals, Inc. (Luo v. Spectrum Pharmaceuticals, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Campbell v. Wood
18 F.3d 662 (Ninth Circuit, 1994)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Buchanan v. United States
15 F.2d 496 (Eighth Circuit, 1926)
Cindy Castillo v. Bank of America, Na
980 F.3d 723 (Ninth Circuit, 2020)
Johnson v. Donaldson
3 F. 22 (U.S. Circuit Court for the District of Southern New York, 1880)
Ferrari v. Gisch
225 F.R.D. 599 (C.D. California, 2004)